Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Member News
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...
Related or similar articles
May 9, 2019
Labshares Newton Selects Savran Technologies as Winner of First Launch@Labshares Competition Valued at $50K
Second Launch@Shares Competition Announced in Collaboration with MTTC/MALSI Conference and MassBio’s MassCONNECT Program
Press Releases
March 8, 2024
Labshares Collaborates with Mispro and Charles River Accelerator and Development Lab (CRADL) to Create New Vivarium Partnerships
Exciting news at Labshares! We've partnered with Mispro and CRADL to enhance our shared lab spaces in Boston, offering members preferred pricing for top-notch research facilities.
Labshares News
December 9, 2021
Bulfinch Leases 40,000 Square Feet to Labshares
BOSTON & NEWTON, Mass.--(BUSINESS WIRE)--The Bulfinch Companies, Inc. (Bulfinch), a commercial real estate and investment firm, and Labshares Newton today announced the expansion of the life science and biotech co-working incubator at Chapel Bridge..
Labshares News